期刊文献+

GEMOX方案治疗铂类耐药复发及难治性卵巢癌疗效观察 被引量:1

下载PDF
导出
摘要 目的:探讨GEMOX方案(吉西他滨联合奥沙利铂)治疗铂类耐药复发及难治性卵巢癌的疗效和不良反应。方法:我科自2008年10月至2013年10月应用吉西他滨联合奥沙利铂治疗复发、难治性上皮性卵巢癌患者20例,其中3例为难治性、17例为铂类耐药复发。所有患者均予吉西他滨1000mg/m2第1、8天静脉给药,奥沙利铂130mg/m2,第1天静脉给药。3周为1周期,每个患者至少接受2周期化疗用药。2个周期后评价疗效、疾病控制率,每周期均监测不良反应。结果:20例患者共完成96个化疗周期,有效率为40%(8/20),疾病控制率为75%(15/20);主要毒性反应为骨髓抑制、神经毒性和消化道反应。结论:GEMOX方案治疗铂类耐药复发、难治性上皮性卵巢癌疗效较好,毒性反应可以耐受。
出处 《承德医学院学报》 2014年第6期493-494,共2页 Journal of Chengde Medical University
  • 相关文献

参考文献5

  • 1万小云,程蓓,谢幸.难治性与复发性卵巢癌的诊治问题[J].中国实用妇科与产科杂志,2008,24(1):26-28. 被引量:9
  • 2Pectasides D, Xiros N, Papaxoinis G, et al. Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinumrefiactory/resistant, paclitaxel- pretreated, ovarian carcinoma[J]. Gynecol Oncol, 2008, 108( 1): 47-52.
  • 3谢聪,李玉玲,尹如铁,王丹青.吉西它滨在上皮性卵巢癌中的研究发展[J].中华妇幼临床医学杂志(电子版),2009,5(5):65-69. 被引量:5
  • 4Hamett E Buck M, Beale P, et al. Phase II study of gemeitabine and oxaliplatin in patients with recurrent ovarian cancer:an Australian and New Zealand Gynaecological Oncology Group study[J]. Int J Gynecol Cancer, 2007, 17(2): 359-366.
  • 5Vici P, Sevgi D, Pizzuti L, et al. Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients[J]. J Exp Clin Cancer Res, 2013, 32(1): 49.

二级参考文献9

  • 1Garc a-Velloso MJ,Jurado M,Ceamanos C,et al.Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma[J].Eur J Nucl Med Mol Imaging,2007,34:1396-1405.
  • 2Elit L,Zitzelsberger L,Fung-Kee-Fung M,et al.Use of systemic therapy in women with recurrent ovarian cancer-development of a national clinical practice guideline[J].Gyneeol Oncd,2007,106:181-192.
  • 3Salani R,Santillan A,Zahurak ML,et al.Secondary cytoreductive surgery for localized recurrent epithelial ovarian cancer[J].Cancer,2007,109(4):685-691.
  • 4Tebos SJ,Sayer BA,Palmer JM,et al.Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma[J].Gynecol Oncol,2007,106:482-487.
  • 5Perez-Gracia JL,Carrasco EM.Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings:systematic rcview of the literature and implications for future research[J].Gynecol Oncol,2002,84:201-209.
  • 6Wilailak S,Linasmita V,Srisupundit S.Phase Ⅱ study of highdose megestrol acetate in platinum-refractory epithelial ovarian cancer[J].Anticancer Drugs,2001,12:719-724.
  • 7Gnmdker C,Emons G.Role of gonadotropin-releasing hormone(GnRH)in ovarian cancer[J].Reprod Biol Endocrinol,2003,1:65-68.
  • 8Verschraegen CF,Westphalen S,HuW,et al.Phase Ⅱstudy of cetrorelix,a Inteinizing hormone-releasing hormone antagonist in patient with platinum-resistant ovarian cancer[J].Gynecol Oncol,2003,90:552-559.
  • 9Devansu Tewari,Bradley J. Monk,Mark Hunter,Camille A. Falkner,Robert A. Burger. Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma[J] 2004,Investigational New Drugs(4):475~480

共引文献12

同被引文献24

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部